CSE1L in enhancing the effect of defactinib on gastric cancer cells via the inhibition of FAK phosphorylation
Xin He, Yating Wang, Yanning Zhang, Arvind Sahu, Khaldoun Almhanna, Yan Liu · 2024
Read CSE1L in enhancing the effect of defactinib on gastric cancer cells via the inhibition of FAK phosphorylation by Xin He, Yating Wang, Yanning Zhang, Arvind Sahu, Khaldoun Almhanna, Yan Liu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11730453.txt.
Description
Xin He and five co-authors study, in a 2024 paper, a gene that may help a drug work better against stomach cancer. The gene, CSE1L, is more active in stomach tumors than in healthy tissue, and high levels go with worse outcomes. The team asked what the gene does in cancer cells and whether it changes how a drug called defactinib performs.
They removed or boosted the gene in two stomach cancer cell lines. More of the gene sped growth, spread, and sticking to surfaces. Gene scans pointed to the focal adhesion pathway, which anchors cells. The team showed the gene lowers the active form of a key anchor protein, and that this shift strengthens the drug's effect. The finding names a possible pairing for therapy.
Catalog record
| CREATOR | Xin He, Yating Wang, Yanning Zhang, Arvind Sahu, Khaldoun Almhanna, Yan Liu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |